1
|
Lei JY, Li Y, Li CM, Xiong XL, Feng CC, Weng WJ, Peng XM, Zhou DH, Huang K. [Effect of Low-Dose Recombinant Interleukin-2 Therapy on Immunocyte Subsets in Children with Solid Tumor]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2024; 32:445-449. [PMID: 38660850 DOI: 10.19746/j.cnki.issn.1009-2137.2024.02.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/26/2024]
Abstract
OBJECTIVE To evaluate the effect of low-dose recombinant interleukin-2 (rIL-2) therapy on immunocyte subsets and its side effects in children with solid tumor. METHODS A total of 22 children (11 males and 11 females) with solid tumor in our department from December 2012 to November 2017 were selected, with a median age of 9 (3-16) years old when starting IL-2 therapy. ALL surgeries and chemotherapy of children had been completed before low-dose rIL-2 therapy, and 17 cases achieved complete remission (CR) and 5 cases achieved partial remission (PR). A low-dose rIL-2 therapy was given 1 month after chemotherapy for 1 year: 4×105 IU/(m2·d), s.c. for every other day, 3 times per week. The immunocyte subsets were detected every 3 months until the end of treatment, meanwhile, disease condition and therapy-related side effects were followed up. RESULTS After low-dose rIL-2 therapy in 22 children, the absolute values of CD3+ T cells, CD3-CD56+ natural killer cells, CD3+CD4+ helper T cells (Th) and CD3+CD8+ cytotoxic T cells were up-regulated remarkably, as well as Th/suppressor T cells (all P < 0.05). While, there were no significant differences in absolute value and proportion of CD4+CD25+CD127- Treg cells during therapy. Among the 17 children who achieved CR before rIL-2 therapy, 14 cases continued to maintain CR after therapy, while 3 cases relapsed, and with 2 died after treatment abandonment. The 5 children who achieved PR before low-dose rIL-2 therapy were evaluated CR by PET/CT scan after treatment. In the early stage of low-dose rIL-2 therapy, 1 child developed skin rashes at the injection sites, and 2 children ran a slight to mild transient fever. Their symptoms disappeared without any organ damage after symptomatic treatment. CONCLUSION Low-dose rIL-2 therapy has good drug tolerance, and changes the distribution of anti-tumor immune-cell subgroup in peripheral blood of children with solid tumor remarkably without up-regulation of absolute value and ratio of Treg cells.
Collapse
Affiliation(s)
- Jia-Ying Lei
- Department of Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
| | - Yang Li
- Department of Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China.E-mail:
| | - Chun-Mou Li
- Department of Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
| | - Xi-Lin Xiong
- Department of Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
| | - Chu-Chu Feng
- Department of Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
| | - Wen-Jun Weng
- Department of Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
| | - Xiao-Min Peng
- Department of Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
| | - Dun-Hua Zhou
- Department of Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
| | - Ke Huang
- Department of Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
| |
Collapse
|
2
|
Gui L, Zhang W, Shi JN, Zhang WJ, Yang ZN, Ma YC, Chen BA. [Clinical Characteristics and Prognosis of Patients with Hematological Malignancies Superimposed with Solid Tumors]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2022; 30:924-929. [PMID: 35680828 DOI: 10.19746/j.cnki.issn.1009-2137.2022.03.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
OBJECTIVE To investigate the clinical characteristics and prognosis of hematological malignancies superimposed patients with solid tumors. METHODS The clinical data of 30 patients with more than two kinds of malignancy (the second is hematological malignancy) from October 2011 to October 2020 in Department of Hematology, Jiangning Hospital Affiliated to Nanjing Medical University were collected and analyzed retrospectively. The overall survival time was used as the prognostic evaluation standard, and the survival of patients were analyzed by KaplanMeier method. Logrank test and Cox regression model were used to carry out univariate and multivariate retrospective analysis on clinical and laboratory parameters of 30 patients. RESULTS Among 30 cases, 20 were male, 10 were female, the median age of onset of the second tumor was 70 years old. The common types of the secondary hematological malignancies to solid tumors are myelodysplastic syndrome, acute myeloid leukemia, multiple myeloma. Univariate analysis showed that patients' gender, age, type of solid tumors, the onset of interval between two kinds of tumor, chromosome karyotype were not related to do with the patients' overall survival time. Type of hematologic disease, ECOG score were associated with patients' overall survival time, and the multivariate analysis showed that the type of hematologic disease and ECOG score were independent risk factors for patients with poor prognosis. CONCLUSION Patients superimposed with solid tumors complicated with myelodysplastic syndrome or acute leukemia and ECOG score ≥3 have poor prognosis and shorter overall survival time, which are independent risk factors influencing the prognosis. Bone marrow injury, immune dysfunction and genetic susceptibility after chemoradiotherapy may be the main causes of these diseases.
Collapse
Affiliation(s)
- Lin Gui
- Department of Hematology, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing 211100, Jiangsu Province, China,Department of Hematology, Zhongda Hospital Southeast University, Nanjing 210009, Jiangsu Province, China
| | - Wei Zhang
- Department of Hematology, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing 211100, Jiangsu Province, China,Email:
| | - Jing Ning Shi
- Department of Hematology, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing 211100, Jiangsu Province, China,Email:
| | - Wen Jing Zhang
- Department of Hematology, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing 211100, Jiangsu Province, China
| | - Zhi Nan Yang
- Department of Hematology, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing 211100, Jiangsu Province, China
| | - Yong Chao Ma
- Department of Hematology, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing 211100, Jiangsu Province, China
| | - Bao An Chen
- Department of Hematology, Zhongda Hospital Southeast University, Nanjing 210009, Jiangsu Province, China
| |
Collapse
|